Pipeline of Acute Respiratory Distress Syndrome Market Research H2 2015

ReportsnReports adds Acute Respiratory Distress Syndrome market research to its database.

This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects.

Inquire more about this research at http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=445061 .

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete research is available at http://www.reportsnreports.com/reports/445061-acute-respiratory-distress-syndrome-pipeline-review-h2-2015.html

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2015 10
Number of Products under Development for Acute Respiratory Distress Syndrome – Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Acute Respiratory Distress Syndrome – Pipeline by Altor BioScience Corporation, H2 2015 19
Acute Respiratory Distress Syndrome – Pipeline by Athersys, Inc., H2 2015 20
Acute Respiratory Distress Syndrome – Pipeline by BioMarck Pharmaceuticals, Ltd., H2 2015 21
Acute Respiratory Distress Syndrome – Pipeline by Faron Pharmaceuticals Oy, H2 2015 22
Acute Respiratory Distress Syndrome – Pipeline by FirstString Research, Inc., H2 2015 23
Acute Respiratory Distress Syndrome – Pipeline by GlaxoSmithKline Plc, H2 2015 24
Acute Respiratory Distress Syndrome – Pipeline by Histocell S.L., H2 2015 25
Acute Respiratory Distress Syndrome – Pipeline by Myelo Therapeutics GmbH, H2 2015 26
Acute Respiratory Distress Syndrome – Pipeline by Phylogica Limited, H2 2015 27
Acute Respiratory Distress Syndrome – Pipeline by Serendex Pharmaceuticals A/S, H2 2015 28
Acute Respiratory Distress Syndrome – Pipeline by Silence Therapeutics Plc, H2 2015 29
Acute Respiratory Distress Syndrome – Pipeline by Therabron Therapeutics, Inc., H2 2015 30
Assessment by Monotherapy Products, H2 2015 31
Number of Products by Stage and Target, H2 2015 33
Number of Products by Stage and Mechanism of Action, H2 2015 35
Number of Products by Stage and Route of Administration, H2 2015 37
Number of Products by Stage and Molecule Type, H2 2015 39
Acute Respiratory Distress Syndrome Therapeutics – Recent Pipeline Updates, H2 2015 71
Acute Respiratory Distress Syndrome – Dormant Projects, H2 2015 81
Acute Respiratory Distress Syndrome – Dormant Projects (Contd…1), H2 2015 82
Acute Respiratory Distress Syndrome – Discontinued Products, H2 2015 83